Scroll Top

AI Applications in Biopharma Summit 2018

Where You Are Headed, You Can’t Go It Alone – October 25, 2018
Harry Glorikian, General Partner, New Ventures Funds, and author of the top-selling book, MoneyBall Medicine: Thriving in the New Data- Driven Healthcare Market, will kicking off the day setting the stage for the discussions that will take place over the course of the Summit and identify the key questions that need to be asked and answered. What organizational structures will produce the best results? Should you partner or make acquisitions? How do you best structure post-acquisition assets? How do you make the cultural shift to change workflows around the technology to get real benefit for the AI tools, instead of trying to fit technology into existing workflows? And most importantly, how do you identify the problems the technology is best suited to solve? Wherever you are on the road to AI adoption, you can’t go it alone so join the conversation and help drive the movement forward.

About Harry Glorikian

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.

He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Harry holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.